Gastrointestinal Cancer

To integrate these layers, we propose effective immunogenic burden (EIB) as a conceptual framework that describes the state in which tumor mutations generate high-quality neoantigen peptides that are successfully presented on HLA molecules for T-cell recognition. By integrating neoantigen quality and antigen-presentation capacity beyond TMB, EIB provides a clinically interpretable basis for understanding heterogeneous responses to ICB in GI cancers.

We highlight the utility of a liquid biopsy approach to aid selection of GI cancer patients harbouring rare POLE mutations for immunotherapy, leading to complete metabolic response in addition to radiologic responses and extended survival in all three patients. This study advocates for specialised multi-disciplinary teams performing shared clinical decision making to advance personalised care and improve outcomes of a subset of GI cancer patients with a poor prognosis.

P=N/A, N=40, Completed, Abramson Cancer Center at Penn Medicine | Recruiting --> Completed | N=80 --> 40

P=N/A, N=100, Enrolling by invitation, Tufts Medical Center | Not yet recruiting --> Enrolling by invitation

P1/2, N=52, Recruiting, Bold Therapeutics Inc. | N=38 --> 52

The incidence of FGFRi-associated nail toxicities varies by agent and can affect quality of life and treatment adherence. The pathogenesis remains unclear, and no predictive biomarkers exist. Further research into optimized management and preventative strategies is needed. Early recognition and proactive multidisciplinary management are essential to minimizing complications and maintaining oncologic treatment continuity. &nbsp.

P2, N=90, Not yet recruiting, Chinese PLA General Hospital

P=N/A, N=100, Recruiting, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Mar 2026

P=N/A, N=56, Recruiting, Ankara Etlik City Hospital

P=N/A, N=1138, Completed, Fudan University | Recruiting --> Completed | Trial completion date: Apr 2029 --> Jul 2025 | Trial primary completion date: Jan 2026 --> Jul 2025

P=N/A, N=600, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2029 --> Feb 2028 | Trial primary completion date: Sep 2028 --> Nov 2027

Subsequent imaging confirmed a renal mass concordant with the IHC findings. This case underscores the importance of recognizing morphologic clues and using a targeted IHC panel when evaluating clear cell neoplasms in the gastrointestinal tract.